Line item 3: cell culture identification (380801.BSV) units: each catalog#: 380801.BSV
Ended Awarded
- Contract number
- HHSN26100011
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77 Part of Sigma-Aldrich Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $89,114
Award facts
- Opportunity
-
- N02RC3600485 Solicitation number
- Biosafety Testing of GMP Master Cell Banks (MCB) and Retroviral Vectors for NCI Clinical Trials Award Notice · Posted Mar 7, 2013
- Contract value 100% obligated
- $89,113.67 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
About this award
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Bioreliance Corporation, a foreign-owned, for-profit organization, for $89,113.67. The contract is for LINE ITEM 3: CELL CULTURE IDENTIFICATION (380801.BSV) services.
Bioreliance Corporation, through its Life Sciences Services Division, provides specialized testing services to support investigational new drug applications, including endotoxin, sterility, and general safety testing. The company has been a consistent contractor for HHS agencies, particularly the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC), supporting their health initiatives. This contract does not have a set-aside designation, indicating Bioreliance's competitive standing in its field.
Bioreliance's parent company is Sigma-Aldrich Corporation, a leading supplier of laboratory chemicals and related services to various industries, including biotechnology and pharmaceutical research.
Quick answers
Who was awarded contract HHSN26100011?
HHSN26100011 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on November 22, 2013.
How much is contract HHSN26100011 worth?
The government has obligated $89,114 on HHSN26100011.
Is contract HHSN26100011 an order under another contract?
Yes. HHSN26100011 is a delivery order under HHSN261201300026I, an indefinite delivery contract.
Was contract HHSN26100011 competed?
The extent of competition for HHSN26100011 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award